TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

NCT02322281 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

149

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor discontinued development of CO-1686 for NSCLC

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Rociletinib
DRUG: Pemetrexed or gemcitabine or paclitaxel or docetaxel

Sponsor

Clovis Oncology, Inc.